Streetbeat News

MDRX

Veradigm Inc

https://www.allscripts.com/

CEO

Paul Black

Employees

6,445

Industry

Computer Systems Design Services

allscripts (nasdaq: mdrx) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. our innovative solutions connect people, places and data across an open, connected community of health™. connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. to learn more, visit www.allscripts.com, twitter, youtube and blog.allscripts.com.

Open

5.40

Mkt cap

565M

Volume

7.7K

High

5.50

P/E Ratio

10.94

52-wk high

11.80

Low

5.17

Div yield

N/A

52-wk low

4.00

In Tuesday's pre-market session, health care stocks saw significant movements. Janux Therapeutics and Viking Therapeutics led the gainers with over 90% increases in their stock prices, while NRX Pharmaceuticals and Veradigm were among the top losers, experiencing over 20% declines. Notably, TransMedics, Ligand Pharmaceuticals, and Hims & Hers Health reported their Q4 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:06 pm

Veradigm has entered into a definitive agreement to acquire ScienceIO for a purchase price of $140M in cash. The deal will be funded through cash on hand without the need for financing. Approximately $44M of the purchase price is deferred, payable over the first three anniversaries of the closing. Veradigm has also reaffirmed its fiscal 2023 financial projections.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:28 pm

Veradigm announced it will not meet Nasdaq's deadline of February 27, 2024, for filing required financial statements, risking suspension of trading. The company is working to file the necessary documents and has adopted a stockholder rights plan in anticipation of potential trading suspension.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:25 pm

Today's session highlighted significant options activity in the Health Care sector, with notable trades in stocks like MDRX, IBRX, ABT, BCRX, TEVA, TMO, TGTX, CI, MRK, and HUM. The activity ranged from bullish to bearish sentiments across various expiration dates and strike prices, indicating diverse market expectations and strategies among investors.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:35 pm

Veradigm Inc. (NASDAQ:MDRX), in partnership with the American College of Cardiology (ACC), has launched TRANSFORM VAX, an initiative aimed at improving cardiovascular health through increased influenza vaccination education. The initiative leverages Veradigm's healthcare data and technology solutions to deliver ACC-sponsored vaccination education messaging to cardiology practices. This effort is supported by the CDC/HHS and seeks to address the implementation gaps in influenza vaccination for patients with cardiovascular disease, which is associated with a significantly lower risk of adverse cardiovascular events.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 1:14 pm

RBC Capital analyst Sean Dodge has maintained an Outperform rating on Veradigm (NASDAQ:MDRX) but has cut the price target from $22 to $11.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:06 pm

WD-40 Company (NASDAQ:WDFC) shares surged over 17% after reporting Q1 earnings of $1.28 per share, surpassing estimates of $1.05 per share, and sales of $140.42 million, above the expected $134.37 million. Other stocks experienced significant movements in Wednesday's mid-day session, with various companies reporting funding, FDA interactions, earnings, and other corporate updates.

Portfolio Pulse from Avi Kapoor

January 10, 2024 | 6:06 pm

Veradigm, a healthcare information technology solutions unit, has provided its fiscal year 2023 non-GAAP earnings per share (EPS) guidance to be in the range of $0.79 to $0.88.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:15 pm

Veradigm, a healthcare information technology solutions provider, has projected its revenue for the fiscal year 2023 to be between $608 million and $622 million.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:14 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Exicure (XCUR) saw a 29.8% increase, while Telesis Bio (TBIO) rose by 21.88%. Jin Medical International (ZJYL) increased by 21.33%, Estrella Immunopharma (ESLA) by 15.78%, Amarin Corp (AMRN) by 15.35%, and Bio-Path Hldgs (BPTH) by 12.99%. Conversely, Aclaris Therapeutics (ACRS) fell by 14.1%, Forian (FORA) by 9.93%, Veradigm (MDRX) by 9.86%, cbdMD (YCBD) by 8.87%, ThermoGenesis Holdings (THMO) by 8.58%, and Qilian Intl Hldg Gr (QLI) by 8.32%.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.